Sarcopenic Obesity

Sarcopenic obesity drives functional decline in older adults with growing recognition in the GLP-1 era. The session covers EWGSOP2 and GLIM diagnostic criteria, resistance training in older adults as the foundation, anti-myostatin trials (bimagrumab phase 2 in obesity, ZEPDISC obesity-sarcopenia), protein and vitamin-D protocols, GLP-1 effects on muscle mass and the preservation strategies, and the integration with comprehensive geriatric assessment. Discussion addresses functional outcomes vs simple weight loss, falls risk in obesity treatment, sarcopenia in cancer cachexia, the future of muscle-preserving pharmacotherapy, BCAA supplementation evidence, and the comparison of bariatric surgery vs GLP-1 effects on muscle in older adults.